Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: A prospective observational study

Medical Mycology

Volumn 49, Issue 7, 2011, Pages 688-693

  Kohno, Shigeru ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Miyazaki, Yoshitsugu ^b   Ogawa, Kenji ^c   Amitani, Ryoichi ^d   Niki, Yoshihito ^e   Kurashima, Atsuyuki ^f  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c National Hospital Organization Higashi Nagoya National Hospital   (Japan)

^d OSAKA RED CROSS HOSPITAL   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f Japan Anti Tuberculosis Association   (Japan)

Author keywords

Chronic pulmonary aspergillosis; efficacy; micafungin; observational study; safety

Indexed keywords

MICAFUNGIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INJECTION SITE EXTRAVASATION; JAPANESE; LUNG ASPERGILLOSIS; MALE; OBSERVATIONAL STUDY; PERIPHERAL EDEMA; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHRONIC DISEASE; DRUG-INDUCED LIVER INJURY; ECHINOCANDINS; FEMALE; HUMANS; JAPAN; LIPOPEPTIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ASPERGILLOSIS; TREATMENT OUTCOME;

ASPERGILLUS; CANDIDA;

EID: 80052582020     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.561369     Document Type: Review

References (32)

1. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15 : 569-574. (Pubitemid 36026968)
2. Marr KA, Carter RA, Crippa F, et al . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34 : 909-917. (Pubitemid 34229758)
3. Kume H, Yamazaki T, Abe M, et al . Epidemiology of visceral mycoses in patients with leukemia and MDS-analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Nippon Ishinkin Gakkai Zasshi 2006; 47 : 15-24.
4. Koch S, Hohne FM, Tietz HJ. Incidence of systemic mycoses in autopsy material. Mycoses 2004; 47 : 40-46. (Pubitemid 38375597)
5. Denning DW. Invasive aspergillosis. C lin Infect Dis 1998; 26 : 781-805. (Pubitemid 28180316)
6. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 : 358-366. (Pubitemid 32173620)
7. Denning DW, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 : S265- 280. (Pubitemid 37260464)
8. Walsh TJ, Anaissie EJ, Denning DW, et al . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 : 327-360. (Pubitemid 351265310)
9. Jantunen E, Ruutu P, Niskanen L, et al . Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19 : 801-808. (Pubitemid 27207896)
10. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 : 986-989.
11. Martino R, Subira M, Rovira M, et al . Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116 : 475-482. (Pubitemid 34155525)
12. Kristan SS, Kern I, Music E. Invasive pulmonary aspergillosis. R espiration 2002; 69 : 521-525. (Pubitemid 35404295)
13. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 : S207-238. (Pubitemid 41038572)
14. Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot ( Tokyo ) 1999; 52 : 674-676. (Pubitemid 29378227)
15. Tawara S, Ikeda F, Maki, K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44 : 57-62. (Pubitemid 30010672)
16. Hatano K, Morishita Y, Nakai T, et al . Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus . J Antibiot ( Tokyo ) 2002; 55 : 219-222. (Pubitemid 34285463)
17. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. C lin Infect Dis 2006; 42 : 1171-1178.
18. Ikeda F, Tanaka S, Ohki H, et al. Role of micafungin in the antifungal armamentarium. Curr Med Chem 2007; 14 : 1263-1275. (Pubitemid 46739326)
19. Kuse ER, Chetchotisakd P, da Cunha CA, et al . Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369 : 1519-1527. (Pubitemid 46670281)
20. Pappas PG, Rotstein CM, Betts RF, et al . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45 : 883-893. (Pubitemid 47580382)
21. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profi le and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38 : 47-51. (Pubitemid 43923089)
22. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fl uconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21 : 899-907. (Pubitemid 40477250)
23. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49 : 3317-3324. (Pubitemid 41060577)
24. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24 : 654-661. (Pubitemid 41667052)
25. Kohno S, Masaoka T, Yamaguchi H, et al . A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36 : 372-379. (Pubitemid 38967695)
26. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, doubleblind, parallel-group, dose-response study of micafungin compared with fl uconazole for the treatment of esophageal candidiasis in HIVpositive patients. Clin Infect Dis 2004; 39 : 842-849. (Pubitemid 39244300)
27. van Burik JA, Ratanatharathorn V, Stepan DE, et al . Micafungin versus fl uconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39 : 1407-1416. (Pubitemid 39518200)
28. Pettengell K, Mynhardt J, Kluyts T, et al . Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20 : 475-481. (Pubitemid 39120260)
29. Tamura K, Urabe A, Yoshida M, et al . Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009; 50 : 92-100.
30. Izumikawa K, Ohtsu Y, Kawabata M, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007; 45 : 273-278. (Pubitemid 46705845)
31. Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61 : 410-418.
32. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [homepage on the Internet]. Switzerland: Harmonised Tripartite Guideline; Current step 4 version [updated 1994 October 27; cited 1995 March]. Clinical Safety Data Management: defi nitions and Standards for Expedited Reporting E2A. Available from the website: .